Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Interest Expense

Cost of servicing the company's debt during the period.

Incyte CorporationNASDAQ: INCY

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $581K fell 2.2% year over year, ahead of the -5.0% change in trailing-twelve-month interest expense. Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.2% holds above the trailing-twelve-month pace of -5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$581K+2.1% QoQ
Last fiscal yearDec 2025
$2.43M+6.5% YoY
LTMJun 2026
$2.32M-5.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.2%——
1 year+6.5%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.43M USD
Year-over-year change
+6.5%
4-year CAGR
+6.2%

Interest Expense vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 interest expense of $2.32M is the 5th highest of the 11 companies compared; the peer median is $664K.
  • Its year-over-year change of -5.0% is the 3rd highest of 5, against a peer median of +11.4%.
  • Interest expense amounts to 0.0% of revenue for INCY, versus a peer median of 1.1%.
INCY Competitors Peer median
Interest Expense for INCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$269.28M —+42.7%6.5%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$55.4M +51.4%-9.7%0.4%
LEGNLegend Biotech CorporationLTM Sep 2026$15.08M -28.5%+25.6%1.1%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$6.19M +69.9%+37.9%2.1%
INCYIncyte CorporationLTM Jun 2026$2.32M -5.0%-3.1%0.0%
VSTMVerastem, Inc.LTM Mar 2026$1.33M -63.4%-18.9%2.7%
EXELExelixis, Inc.LTM Jul 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding INCY) $664K+11.4%+25.6%1.1%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.